Announcement of The Consolidated Financial Report for The 3rd Quarter of 2024
2024.11.13
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2024/11/13 | Time of announcement | 18:06:28 |
| Subject | Announcement of The Consolidated Financial Report for The 3rd Quarter of 2024 | ||||
| Date of events | 2024/11/13 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2024/11/13 2.Date of the audit committee approved:2024/11/13 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2024/01/01~2024/09/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):4,181,720 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,526,864 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):1,043,396 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,217,135 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):975,799 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):915,116 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):3.68 11.Total assets end of the period (thousand NTD):10,644,722 12.Total liabilities end of the period (thousand NTD):3,674,419 13.Equity attributable to owners of parent end of the period (thousand NTD):6,209,889 14.Any other matters that need to be specified:None. |
||||